Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22638209 | 0.87 | PDE4A (0.35) | PTPN11PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22632665 | 0.85 | ALK (0.35) | PTPN11PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22632891 | 0.84 | L3MBTL1 (0.34) | PTPN11PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL31258427 | 0.83 | RORC (0.35) | — | |
| SCHEMBL22632422 | 0.83 | RORC (0.35) | — | |
| SCHEMBL22632745 | 0.83 | L3MBTL1 (0.32) | PTPN11PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22632642 | 0.82 | PTGS2 (0.32) | PTPN11 | |
| SCHEMBL29414678 | 0.82 | PTGS2 (0.32) | PTPN11 | |
| SCHEMBL22632786 | 0.80 | CD4 (0.42) | — | |
| SCHEMBL31258414 | 0.80 | CD4 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4523692-A2 | MODULATORS OF THR-SS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | PTPN11 1401/4885PDE4A 1693/4885PDE4B 1491/4885 |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | PTPN11 1381/4885PDE4A 1527/4885PDE4B 1292/4885 |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | PTPN11 1401/4885PDE4A 1693/4885PDE4B 1491/4885 |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | PTPN11 1278/4885PDE4A 1655/4885PDE4B 1464/4885 |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | PTPN11 1278/4885PDE4A 1655/4885PDE4B 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.